Prescription Pattern Analysis of Type II Diabetes Mellitus Inpatients and Associated Co-Morbidities by Ashok, Purnima et al.
Ashok et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2020; 10(3):42-47 
ISSN: 2250-1177                                                                                  [42]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.05.2020 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits 
unrestricted non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                            Research Article  
Prescription Pattern Analysis of Type II Diabetes Mellitus Inpatients and 
Associated Co-Morbidities 
Dr. Purnima Ashok, Vijesh Thollur Subrahmanian, Rinju Raj*, Rahul Rajendra Babu, Ramshad T. P., Kevin L. 
Department of Pharmacy Practice, K.L.E College of Pharmacy, Bengaluru-10, Karnataka, India 
 
ABSTRACT  
Background: The present study was planned to assess the prescription pattern analysis of Type II Diabetes Mellitus and associated co-
morbidities. As per WHO, the worldwide prevalence of DM will reach 366 million by 2030. Evaluating drug prescription pattern is a major 
aspect of patient care, which is used as a measure of the quality of care provided. Objectives: Primary objectives of the study were to highlight 
the current prescription pattern trends in patients having diabetes mellitus with or without other co-morbid conditions, to ensure safety and 
rational use of prescribed regimen. And the secondary objectives of the study were to analyse the demographic information of the enrolled 
patients and also to identify and analyse the prescriptions with polypharmacy. Materials and Methods: A prospective observational study was 
conducted to analyse the prescribing pattern of anti-diabetic drugs. The study incorporated 100 Type II DM inpatients having comorbid 
conditions. The study has been conducted with the help of WHO prescribing indicator scale. It is used to analyse drug class, generic and 
branded drugs, fixed dose combination and dosage form. Patient data was collected and medical data records were analysed daily till discharge 
from hospital. Results: It was found that most of the drugs have been prescribed are purely from Karnataka Essential Medicine list (KEML). 
And percentages of medicines prescribed on their generic name were 76%. About 51% of patients were treated only with oral hypoglycemi c 
agents. Whereas, 38% were treated with Insulin and 11% were treated with both oral hypoglycemic agents and Insulin. Conclusion: Improved 
rational use of prescription by using Essential Medicine List (EML).And also ensured the appropriateness of prescription by using WHO scale. 
Several Adverse Drug Reactions (ADR)have been reported and which leads to improved  prescription pattern.  
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INTRODUCTION 
DM is defined as a heterogeneous metabolic disorder 
characterised by chronic hyperglycaemia with disturbance 
of carbohydrate, fat and protein metabolism. Metabolic 
syndrome such as insulin resistance syndrome can increase 
the risk of DM.[1] 
Diabetes symptoms are frequent urination, excessive thirst, 
blurred vision, sweating, sudden weight loss, slow healing 
sores and fatigue. Organ damage and dysfunctions etc. are 
the after effects of type II DM.[1,2] 
Diabetes are of 3 types: Type I, Type II, and Gestational 
diabetes. 
If DM is not treated properly or is for long-term then it can 
leads to shock, cardiovascular disease, chronic kidney 
disease and permanent damage to the eyes. DM patients 
should manage daily dietary intake because the patient have 
to take oral hypoglycaemic agents. Without taking proper 
diet, the patient can suffer from hypoglycaemia. Instead of 
eating a large meal at single time, the patient can have small 
meals 4 to 5 times a day.[3] 
Type II DM comprises of about 80% cases of DM. It was 
called earlier as maturity onset diabetes or Non-Insulin 
Dependent Diabetes Mellitus (NIDDM).[5] 
Major risk factors for Type II DM are Family history, habitual 
physical inactivity, Obesity, previous identification of 
impaired fasting glucose, race, hypertension, history of 
gestational diabetes or delivery of baby heavier than 4kg, 
dyslipidaemia, Poly Cystic Ovarian Syndrome (PCOS), 
History of vascular disease.[2,4] 
Pathogenesis of Type II DM can be explained only through 
certain types of factors and those are, Genetic Factors, 
Constitutional Factors, Insulin Resistance, Impaired Insulin 
Secretion, Increased Hepatic Glucose Synthesis.[3] 
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Antihypeglycemic agents in hospitalized patients include, 
Insulin therapy, Noninsulin therapy include Dipeptidyl 
Peptidase (DPP4) inhibitors or in combination with Insulin, 
Sulfonylurea and Metformin.[5] 
The first line treatment for type II DM will always be lifestyle 
modifications. In case of obese patients with Type II DM, 
Bariatric surgeries is an effective treatment.[5] 
Co morbidity refers to presence of at least one extra chronic 
disease for 6 months or longer. In some cases, diabetic 
patients with clinical complexity are more likely to receive 
high quality care.[5] 
DM is associated with carbohydrate, fat and protein 
metabolism abnormalities which can results in chronic 
microvascular, macrovascular and neuropathic disorders.[7] 
Retinopathy with potential blindness, neuropathy with 
kidney failure and neuropathy with risk of foot ulcers, 
amputation and sexual dysfunction are the long term 
complications of DM.75% of patient deaths are reported due 
to macro vascular events.[2] 
Most common comorbidities are, Retinopathy, Neuropathy, 
Nephropathy, Peripheral Vascular disease and foot ulcer, 
Coronary Artery Disease, Hypertension and Transplantation. 
Treatment for various comorbidities primarily includes 
glycemic control. [5] 
Pharmacological treatment for various co morbidities in 
diabetic patients is as follows: 
1. Hypertension 
 Maintain the blood pressure less than 140/80mmHg. 
 Angiotensin Converting Enzyme (ACE) inhibitors and 
Angiotensin Receptor Blockers (ARBs) are the drug of 
choice. 
 Calcium channel blockers (CCB) or diuretics may be 
considered as a first line agent in some cases. 
 Βeta blockers as second and third line agent. 
2. Coronary Vascular Disease 
 Aspirin therapy 
 Clopidogrel, if allergic to aspirin 
 Βeta blockers for protection from recurrent chronic 
heart disease. 
3. Dyslipidemia 
 Statins 
 Fibrates(its use is controversial) 
 Fibrates, niacin and Statins for hypertriglyceridemia. 
4. Diabetic foot 
 Cilostazol is useful for reducing claudication 
symptoms. 
 Revascularisations 
 Appropriate foot wear and foot care for foot 
lesions.[6,10] 
Foot ulcers are one of the serious medical problems. It 
exhibits a high rate of recurrence and it is extremely difficult 
to heal in case of DM patients. 
In case of general population coronary heart disease is the 
most common cause of death in patients having diabetic End 
Stage Renal Disorder (ESRD) 
25-47% of persons having DM with hypertension as 
comorbidities are having insulin resistance or impaired 
glucose tolerance.[8] 
Prescribing Indicators: 
WHO core prescribing indicators were used to analyse 
prescription patterns. Evaluating drug prescription pattern 
is a major aspect of patient care, which is used as a measure 
of the quality of care provided. In the developing countries 
systematic analysis is prevalent due to irrational dispensing, 
prescribing and administration of medications. Such kind of 
irrational prescribing is unethical and can leads to adverse 
effects incidence, drug resistance, drug interactions etc. As 
per WHO more than half of all medicines are prescribed, 
dispensed or sold inappropriately. Prescription pattern 
studies can be used as a better tool for accurate prescribing, 
dispensing and distribution of drugs. Thus aim of these kinds 
of studies is to provide rational use of drugs. The drug use 
indicators were developed by WHO for rational use of drugs.  
Prescription monitoring studies are crucial to bridge the 
areas such as rational use of drugs. It is very essential to 
conduct studies regarding prescribing patterns in every 
state in India and should use the data that has been collected 
through these studies for improving the quality of patient 
care with the main aim of improving rational drug use. [11] 
MATERIALS AND METHODS 
As per the study criteria those patients fulfilling the 
inclusion criteria were enrolled in the study and those met 
the exclusion criteria were excluded.  
The study design was Prospective, observational study for 6 
months duration. 
Ethical clearance was obtained from institutional ethics 
committee for initiation of study. 100 diabetes patients were 
enrolled within the study from the Department of General 
Medicine, KCG hospital. Prescription pattern analysis of 
Type II DM patients with comorbidities has been conducted 
with the help of WHO core prescribing indicators. Thereby 
found out weather the treatment is rational or irrational. 
Patient data was collected and medical data records were 
analysed daily till discharge from hospital. Prescription 
pattern analysis has done regularly with the help of World 
Health Organisation (WHO) prescribing indicators. 
Patients aged more than 18 years were only included in the 
study. Patients diagnosed with diabetes along with other co 
morbidities were selected. And those are on treatment with 
oral hypoglycemic agents and Insulin therapy was also 
incorporated in the study. 
Patients with conditions such as poisoning and accident 
case, Pediatric patients and Patients with gestational 
diabetes were excluded. Patients visiting outpatient 
departments with or without diabetes mellitus were also be 
excluded. 
Statistical Analysis was done with the help of Microsoft 
Excel. 
RESULTS 
To assess the prescription pattern of type II Diabetes 
mellitus in-patient, the data has been collected from 100 
patients admitted to KCG Hospital and observations are as 
follows: 
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1. WHO Prescribing Indicators:
Table1: Prescription Indicators 
S.N. Prescription Indicators Frequency 
1 Total number of prescriptions  analysed(n) 100 
2 Total number of medicines used in the study(n) 63 
3 Average number of medicines per prescription(n) 7 
4 Percentage of medicines prescribed on their generic name (%) 75.36% 
5 Percentage of drugs prescribed with antibiotics (%) 17.17% 
6 Percentage of prescription contains injectable preparations (%) 90% 
7 Percentage of medicines recommended from KEML (%) 100% 
 
 Patients with co-morbidities were also included in the present study.  
 Number of prescriptions contain polypharmacy were more among studied population as 67% prescriptions contain 
greater than 5 drugs.   
Number of drugs per prescription:  
Table 2: Number of drugs per prescription 
S.N. Number of drugs per prescription(n) Percentage of prescription 
1 Less than Five drugs 33% 
2 More than Five drugs 67% 
 
Table 3: Number of drugs among both genders 
Gender Male Female Male Female 
Less than five drugs 20 13 20% 13% 
More than Five Drugs 43 24 43% 24% 
 
2. Prescription pattern of Anti-Diabetic drugs 
About 51%(n=51) of patients were treated only with oral hypoglycaemic agents whereas, 38% (n=38) were treated with 
Insulin and 11%(n=11) were treated with both oral hypoglycaemic and Insulin.  
 
 
Figure 1: Mode of Treatment 
Maximum numbers of anti-diabetic drugs per prescription were 2, which include both Insulin and oral hypoglycaemic agents. 
Among that, oral hypoglycaemic agents are most commonly used. (Metformin, Glibenclamide, Glimepiride)  
Human Actrapid were the drug of choice of Insulin preparation among enrolled patients.   
 
 
38% 
 
11% 
 
51% 
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Table 4:Anti-Diabetic drugs used 
Sl.N0. Anti-Diabetic drugs used Number of patients (n) Percentage of prescriptions 
1 Metformin 500mg 20 20% 
2 Glibenclamide5mg 4 4% 
3 Glimepiride 1mg 10 10% 
4 Metformin(500mg) + 
Glimepiride(2mg) 
9 9% 
5 Metformin + Glibenclamide 10 10% 
6 Insulin + Metformin 6 6% 
7 Insulin 38 38% 
8 Metformin+ Glimepiride + Insulin 2 2% 
9 Exenatide 1 1% 
 
3. Prescription Pattern of Diabetes Associated Co-Morbidities 
  Diabetes associated co-morbidities                               52% patients. 
 Diabetes associated co-morbidities with other non-diabetes associated 
 co-morbidity                               32% patients. 
 Diabetes with other co-morbidities such as thrombocytopenia or  
pneumonia etc.                               14% patients. 
 Only diabetes without any other co-morbidities                                      2% patients. 
 
Figure 2: Co-Morbid Conditions 
 
• Hypertension, diabetic foot(52%)                              Most common comorbidity. 
•  Maximum number of drugs used to treat hypertension                               One  
• Amlodipine                                Commonly used medicine for hypertension. 
• Symptomatic treatment has been given to diabetic patients with chronic kidney disease which include Lasix for oedema 
and electrolyte replacement for electrolyte imbalance etc  
• Diabetes mellitus patient with diabetic foot are mainly hospitalised as an inpatient for amputation and injectable antibiotic 
preparation mostly prescribed for postoperative surgical site infections.  
• Ceftriaxone, Amikacin and Metronidazole are used together for minimum of five days or maximum to seven days to 
prevent surgical site infection.  
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4. Sex Distribution 
The study participants enrolled in the study, majority of the 
participants were males 64(64%) followed by females 
36(36%). 
 
Figure 3: Gender Distribution 
Table 5: Number of Patients 
S.N. Gender Number of Patients(N) Percentage 
1. Female 36 36% 
2. Male 64 64% 
5. Age wise distribution 
Among 100 participants, majority of age group between 50-
60years (30%) and least were in the age group between 30-
40years (7%). Male patients were more affected in this age 
group (50-60years). 
 
Figure 4: Age Distribution
 
Table 6: Number of patients in different age groups 
S.N. Age(years) Number of patients (n) Percentage of patients 
1. 30-40 7 7% 
2. 41-50 21 21% 
3. 51-60 32 32% 
4. 61-70 26 26% 
5. >70 14 14% 
 
DISCUSSIONS 
As per the study conducted by Manjusha S et al, it is found that 83.81% patients were suffering from concurrent illness where 
hypertension was the most common comorbidity followed by hypertension with atherosclerotic heart disease where in our 
study Hypertension was the common co-morbidity.[11] 
In our study, out of 100 patients, 
 Diabetes associated co-morbidities                                 52% patients  
 Diabetes associated co-morbidities along with other comorbid conditions                         32% patients 
 Diabetes with other co-morbidities                          14% patients 
 only diabetes without any co-morbidities                         2% patients  
Prescription pattern of anti-diabetic drugs were studied and out of 100 patients,  
 Metformin mono therapy                            29% prescriptions 
 Insulin therapy                        28% prescriptions 
 Oral sulfonylureas which include both Glimepiride and Glibenclamide                               14% prescriptions. 
 Combination of Metformin and Sulfonylureas                             19% prescriptions. 
 
These information were comparable to the study done by 
Kevin M Pantolone et al [12].It is found that Metformin and 
Sulfonylureas are commonly prescribed oral hypoglycaemic 
agents and patients receiving only Metformin monotherapy 
in 2018 & 2013 were 63 % and 67% 
respectively.[12]Whereas, in another study by Manjusha et al. 
shows that 58% patients were under monotherapy and 
41.9% were under combination of oral hypoglycemic 
agents.[11]Metformin is widely regarded as first line 
treatment for most of the Type II diabetes patients.[11] Our 
study also supports the same, 56% patients has been 
prescribed with Metformin with other oral hypoglycemic 
agents or insulin preparation. Age distribution of patient 
with DM with or without associated co-morbidities cases in 
age group 50-60 constituted 32% following by 21% in 40-50 
age group , this corresponds to finding by Mohd Mahmood et 
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al, where majority were of age group between 41-60 
(45.53% ) and least were in the age group of 20-
40(6.38%).[3]In our study prevalence of type II DM were high 
in male (63%) which also correlate the result of various 
other study across India. 
CONCLUSION 
The study concluded that anti-diabetic drugs are prescribed 
purely from KEML that show rational prescribing pattern. 
Metformin and oral Sulfonylureas were widely used oral 
hypoglycemic agent as monotherapy or combination of those 
among studied population.  According to the result obtained 
from the study, Male patients are more prone to DM when 
compared to female patients and more number of diabetes 
patients were in between 51-60 years of age due to various 
comorbid conditions like hypertension , diabetic foot etc. 
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